We are live on ! Find out more
PRVB

Provention Bio, Inc. Common Stock
PRVB

Delisted

PRVB was delisted on the 26th of April, 2023.

Back to rankings

115 hedge funds and large institutions have $143M invested in Provention Bio, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 40 increasing their positions, 32 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more call options, than puts

Call options by funds: $3.51M | Put options by funds: $2.22M

25% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 32

8% less funds holding

Funds holding: 125 → 115 (-10)

27% less capital invested

Capital invested by funds: $197M → $143M (-$53.6M)

40% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 25

Holders
115
Holders Change
-10
Holders Change %
-8%
% of All Funds
2.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
40
Reduced
32
Closed
25
Calls
$3.51M
Puts
$2.22M
Net Calls
+$1.29M
Net Calls Change
-$613K

Top Buyers

Rank Fund Capital Flow
1
SC
Sessa Capital
New York
+$9.05M
2
Verition Fund Management
Verition Fund Management
Connecticut
+$4.51M
3
DCM
DG Capital Management
New York
+$3.5M
4
Millennium Management
Millennium Management
New York
+$1.41M
5
N
Nuveen
North Carolina
+$1.35M

Top Sellers

Rank Fund Capital Flow
1
VA
VR Adviser
New York
-$24.5M
2
GGHC
Gilder Gagnon Howe & Co
New York
-$2.43M
3
Charles Schwab
Charles Schwab
California
-$1.52M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.43M
5
First Trust Advisors
First Trust Advisors
Illinois
-$1.15M
Name Holding Trade Value Shares
Change 		Change in
Stake
New York State Common Retirement Fund
51
New York State Common Retirement Fund
New York
$175K -$94.8K -14,758 -35%
JP Morgan Chase
52
JP Morgan Chase
New York
$169K +$6.97K +1,084 +4%
Invesco
53
Invesco
Georgia
$157K +$14.9K +2,313 +10%
VEA
54
Virtus ETF Advisers
New York
$151K -$7.98K -1,242 -5%
HighTower Advisors
55
HighTower Advisors
Illinois
$151K +$5.78K +900 +4%
HSBC Holdings
56
HSBC Holdings
United Kingdom
$150K +$66.7K +10,385 +80%
JF
57
Jump Financial
Illinois
$145K +$145K +22,600 New
VOYA Investment Management
58
VOYA Investment Management
Georgia
$142K – – –
1WM
59
1900 Wealth Management
Texas
$141K – – –
Rafferty Asset Management
60
Rafferty Asset Management
New York
$137K +$55.4K +8,625 +67%
FA
61
Forefront Analytics
Pennsylvania
$135K +$136K +21,102 New
NC
62
NinePointTwo Capital
California
$134K +$135K +21,077 New
MIM
63
MetLife Investment Management
New Jersey
$132K +$80.9K +12,586 +155%
ProShare Advisors
64
ProShare Advisors
Maryland
$132K -$33K -5,129 -20%
RJA
65
Raymond James & Associates
Florida
$128K +$16.4K +2,550 +15%
DekaBank Deutsche Girozentrale
66
DekaBank Deutsche Girozentrale
Germany
$126K – – –
Cambridge Investment Research Advisors
67
Cambridge Investment Research Advisors
Iowa
$125K +$19.9K +3,100 +19%
CSS
68
Cubist Systematic Strategies
Connecticut
$121K -$34.7K -5,399 -22%
Commonwealth Equity Services
69
Commonwealth Equity Services
Massachusetts
$120K +$1.22K +189 +1%
Lido Advisors
70
Lido Advisors
California
$117K – – –
CHAM
71
Clear Harbor Asset Management
Connecticut
$114K – – –
Franklin Resources
72
Franklin Resources
California
$98K +$99K +15,401 New
State Board of Administration of Florida Retirement System
73
State Board of Administration of Florida Retirement System
Florida
$97K – – –
Legal & General Group
74
Legal & General Group
United Kingdom
$97K +$60.4K +9,394 +162%
TI
75
Trexquant Investment
Connecticut
$94K +$94K +14,633 New
1 2
3
4 5

PRVB Hedge Fund Activity: Q3 2021 in Review

115 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q3 2021, worth a combined $143M — down 27% from $197M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of PRVB and 15 opened new positions — a net loss of 10 holders — while 32 trimmed existing stakes and 40 added.

The largest buyer was Sessa Capital, adding an estimated $9.05M. The largest seller was VR Adviser, exiting entirely with an estimated $24.5M sold.

  • 115 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q3 2021, down from 125 in Q2 2021.
  • Funds reported $143M of Provention Bio, Inc. Common Stock stock for Q3 2021, down 27% quarter-over-quarter.
  • 15 funds opened new Provention Bio, Inc. Common Stock positions in Q3 2021 and 25 closed out, a net change of -10 holders.
  • The largest Provention Bio, Inc. Common Stock buyer in Q3 2021 was Sessa Capital, an estimated $9.05M added.
  • The largest Provention Bio, Inc. Common Stock seller in Q3 2021 was VR Adviser, an estimated $24.5M sold.

Based on aggregated 13F filings for Q3 2021.